about
A double blind trial of sulpiride in Huntington's disease and tardive dyskinesiaGait festination and freezing in Parkinson's disease: pathogenesis and rehabilitationEntacapone.Scales for rating motor impairment in Parkinson's disease: studies of reliability and convergent validityA new approach in the assessment of motor activity in Parkinson's diseaseBuspirone in progressive myoclonus epilepsyThe execution of bimanual movements in patients with Parkinson's, Huntington's and cerebellar diseaseNeuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa.A review of the assessment of dyskinesias.Determinants of gait in the elderly parkinsonian on maintenance levodopa/carbidopa therapy.Understanding the Outcomes Measures used in Huntington Disease Pharmacological Trials: A Systematic Review.Assessment of anti-psychotic drugs.Dystonia in Huntington's disease: prevalence and clinical characteristics.Objective measurement of dyskinesia in Parkinson's disease using a force plateAccuracy in the clinical diagnosis of parkinsonian syndromes.A comparative study of simple and choice reaction time in Parkinson's, Huntington's and cerebellar diseaseInsulin-induced hypoglycaemia does not abolish chorea.Periodic alternating nystagmus in a case of hereditary ataxia and its treatment with baclofenA network-based system to improve care for schizophrenia: the Medical Informatics Network Tool (MINT).Botulinum toxin in hemifacial spasm: the challenge to assess the effect of treatment.Electrophysiologic assessments of involuntary movements: tremor and myoclonus.New pharmacotherapy for Parkinson's disease.How Many Dystonias? Clinical Evidence.Insulin-induced hypoglycaemia does not abolish chorea.Quantitative digitography (QDG): a sensitive measure of digital motor control in idiopathic Parkinson's disease.Impaired habituation of long-latency stretch reflexes of the wrist muscles in Huntington's disease.Guidelines for the therapeutic use of botulinum toxin in movement disorders. Italian Study Group for Movement Disorders, Italian Society of Neurology.Quantification of dyskinesia in Parkinson's disease: validation of a novel instrumental method.A quantitative study of levodopa-induced dyskinesia in Parkinson's disease.A comparison of standard Madopar and controlled release Madopar in Parkinson's disease.Minocycline in Huntington's disease: a pilot study.Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.Effects of rivastigmine on motor and cognitive impairment in Huntington's disease.Electromyographic silent period after transcranial brain stimulation in Huntington's disease.Early sympathetic hyperactivity in Huntington's disease.Autonomic dysfunction in presymptomatic and early symptomatic Huntington's disease.Correlation between facial involuntary movements and abnormalities of blink and corneal reflexes in Huntington's chorea.Features of the blink reflex in individuals at risk for Huntington's disease.Gait measures with a triaxial accelerometer among patients with neurological impairment.Disability profiles and objective quantitative assessment in Parkinson's disease.
P2860
Q24515363-4012FC29-51B9-4244-8FB0-08F1CF028FFCQ28289178-6A4654C4-AE5D-4537-AE82-ABACEA751876Q31440112-83760636-90D1-452D-87AF-0DE7F6784228Q33589154-E2DD5A3E-2C6B-4539-BF8F-83A993468FA0Q33590050-1E9A4D60-6012-4594-97A6-E1C39B696650Q33590522-1B66C917-DE98-4D15-A1D7-C2E0F6575FF6Q33590719-980E512B-62CD-4242-A8A6-430265FC8028Q33631368-1868BEE7-A5B5-4E97-AE0D-E3E4FBC7F08BQ33737401-49CC56B6-3415-422D-8FFB-FAB3331760D8Q34357714-DE032908-F1B8-4D0E-BA34-7F3FC75350BEQ34443430-AB4B4450-CBF1-4AC7-B3F8-A24FE5FB84D1Q34448621-FB203716-5062-4D4A-B1B0-C1F88AE37123Q34489281-BD068914-DF57-499B-B35F-048F0230A2D0Q35140804-0B91D6D1-4B17-42E5-A5C4-7F6E8597A422Q36721985-EAFE7523-F64B-421C-A85D-1012E8C76CDAQ36981565-54A2C323-7F16-436F-8A7E-6D6D9B8D5C8AQ37026530-96B4ADCA-B68D-4C5D-BD30-2CD629133506Q37026553-340FEE1A-7F06-46D4-BB68-E7A378E58D9AQ37511036-2A9F39DB-BD8E-4625-A356-AC77671C4BD0Q37974584-C3CA0835-4ABC-4428-AA4C-F11A347BE518Q38215507-B205BC4E-65BB-42D0-9BF0-6381EB0BE632Q38555723-C5A645AF-EE40-4AA6-A5AB-34B2388595C7Q39143529-08FB1415-B3CC-4163-B3FE-4034A968A484Q39279744-CA79F162-22DC-4575-B339-1197C08051F4Q39526701-A328FB41-61C6-44B9-A9EB-0638409158BAQ41196725-6E7A92E3-FA9D-458C-B8DE-A756C80A8B3BQ41669533-8C45A509-415D-455B-A0E0-34675F562220Q41691617-B3030038-66D6-4EDD-B37E-D6546953054CQ42284787-99EA470F-832F-443D-8C3E-27258DEA306FQ44068823-CD836762-975B-4854-B980-1D90918BD874Q44936949-A14CEB18-527A-42C8-917E-0077AB2A2AC5Q45062597-B16E31D2-8D25-4209-921D-60C83CFA7491Q45076727-94FCAD81-E8DE-410B-8F50-0050CC8D24E2Q45290100-EB1691DB-9B78-433F-9236-165010088979Q45295860-BAD9F645-24DA-4556-B712-E733FAB96E2AQ45296254-B6FB138C-D0FD-4F46-84DC-802E3733C56DQ45299204-C9A7E458-19AD-47AD-876D-1027C51947CDQ45304887-A1CB3012-0DFB-44CD-8910-1D45876135E6Q46024441-2B60B2ED-6CA0-4220-A6EB-22876549207CQ46657237-AECAEA46-9C98-4D9D-A067-CF3235CCA6FD
P2860
description
1981 nî lūn-bûn
@nan
1981 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1981 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1981年の論文
@ja
1981年論文
@yue
1981年論文
@zh-hant
1981年論文
@zh-hk
1981年論文
@zh-mo
1981年論文
@zh-tw
1981年论文
@wuu
name
Assessment of extrapyramidal disorders.
@ast
Assessment of extrapyramidal disorders.
@en
Assessment of extrapyramidal disorders.
@nl
type
label
Assessment of extrapyramidal disorders.
@ast
Assessment of extrapyramidal disorders.
@en
Assessment of extrapyramidal disorders.
@nl
prefLabel
Assessment of extrapyramidal disorders.
@ast
Assessment of extrapyramidal disorders.
@en
Assessment of extrapyramidal disorders.
@nl
P2860
P1476
Assessment of extrapyramidal disorders.
@en
P2093
Schachter M
P2860
P304
P356
10.1111/J.1365-2125.1981.TB01118.X
P407
P577
1981-02-01T00:00:00Z